[1] GAO Y，LUO D D. Progress in anti-HIV nucleoside analogues[J]. Foreign Med Sci(Epidemiol Lemol)(国外医学·流行病学传染病学分册)，2001，28(1)：10-15. [2] GRAEME M. The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy[J]. Drugs，2001，61(1)： 19-26. [3] JULIE C A，STUART N. Efavirenz[J]. Drugs，1998，56(6)： 1055-1064. [4] GRAEME M，BRIAN G. Current knowledge and future prospects for the use of HIV protease inhibitors[J]. Drugs，1996，51(5)： 701-712 [5] GREG L P，DAVID P F. Tipranavir[J]. Drugs，2003，63(15)： 1611-1618. [6] KILBY J M. Potent suppression of HIV-1 replication in humans by T-20，a peptide inhibitor of gp41-mediated virus entry[J]. Nat Med，1998，4(11)： 1302-1307. [7] KETAS T J，FRANK I，KLASSE P J，et al. Human immunodeficiency virus types 1 attachment，coreceptor，and fusion inhibitors are active against both direct and trans infection of primary cells[J]. J Virol，2003，77(4)：2762-2767. [8] OLSON W C，KETAS T，NAGASHIMA K，et al. Potent，broad-spectrum inhibition of HIV-1 by the CCR5 antibody PRO 140[C]. Toronto：Intersci Conf Antimicrob Agents Chemother，2000. Sep 17-20，40. 283. [9] SCOZZAFAVA A，MASTROLORENZO A，SUPURAN C T. Non-peptidic chemokine receptors antagonists as emerging anti-HIV agents[J]. J Enzym Inhib Med Chem，2002，17(2)：69-76. [10] OWEN S M，RUDOLPH D，SCHOLS D，et al. Susceptibility of diverse primary HIV isolates with varying co-receptor specificity′s to CXCR4 antagonistic compounds[J]. J Med Virol，2002，68(2)：147-155. [11] TIM I，CAROLINE M P. Lamivudine/zidovudine/avacavir triple combination tablet[J]. Drugs，2003，63(11)： 1089-1098. [12] QI J C. Development and application of anti-AIDS drugs[J]. Chin Pharm Inf(中国制药信息)，2003，19(4)：11-17. [13] ZHOU Y，XI Y X. Status and advance of vaccine used in children[J]. China Prescri Drug (中国处方药)，2 (35)：34-38. [14] MARGARET J，JORGE H. Progress in HIV vaccine development[J]. Curr Opin Pharmacol，2001，1：504-510. [15] FOUSSAT A，BOUCHET-DELBOS L，COUDERC J，et al. Effects of exogenous IL-2 administration on the homeostasis of CD4+ T lymphocytes[J]. J Clin Immunol，2004，24(5)：503-514. [16] MARSILI G，BORSETTI A，SGARBANTI M，et al. On the role of interferon regulatory factors in HIV-1 replication[J]. Ann NY Acad Sci，2003，1010：29-42. [17] BALZATINI J，KARLSSON A，PEREZ-PEREZ，et al. Knocking-out concentration of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus[J]. Virology，1993，196：576-585. [18] RONG L F，QIN D A. Liposome： an ideal carrier of anti-HIV drugs[J]. Chem Life(生命的化学)，1998，18(1)：41-42. [19] KHAWLA A，LUCILA G D，ROBERT L. Preparation and evaluation of sustained release AZT-Loaded microspheres： optimization of the release characteristics using response surface methodology[J]. J Pharm Sci，1996，85(2)：144-149. [20] KHAWLA A，LUCILA T，D ROBERT L. In vivo evaluation of zidovudine (AZT) -loaded ethylcellulose microspheres after oral administration in Beagle dogs[J]. J Pharm Sci，1997，86(5)：554-559. [21] TARUN K M，SRINI T. Preparation of biodegradable microcapsules of zidovudine using solvent evaporation： Effect of the modification of aqueous phase[J]. Int J Pharm，1996，137：187-197. [22] O′HAGAN D T，SRINI M，KAZZAZ J，et al. Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen[J]. Vaccine，2002，20(27-28)：3389-3398. [23] CHIANG C C，MARK L，PRAVEEN T，et al. Formulation development of an oral desage form for an HIV protease inhibitor，AG1284[J]. Int J Pharm，1995，117：197-207. [24] PHILIPS N C，TSOUKAS C. Liposomal encapsulation of azidothymidine result in decreased hematopoletic toxicity and enhanced activity against murine acquired immunodeficiency syndrome[J]. Blood，1992，79：1137-1143. [25] OUSSOREN C，MAGNANI M，FRATERNALE A，et al. Liposomes as carriers of the antiretroviral agent dideoxycytidine-5′-triphosphate[J]. Int J Pharm，1999，180：261-270. [26] KONOPKA K，PRETZER E，PLOWMAN B，et al. Long-term noncytopathic productive infection of the human monocytic leukemia cell line THP-1 by human immunodeficiency virus type 1 (HIV-1ⅢB)[J]. Virology，1993，193：877-887. [27] DUZGUNES N，FLASHER D，PRETZER E，et al. Liposome-mediated therapy of human immunodeficiency virus type-1 and mycobacterium infections[J]. J Lipo Res，1995，5：669-691. [28] ROPERT C，LAVIGNON M，DUBERNET C，et al. Oligonucleotides encapsulated in pH sensitive liposomes are efficient toward Friend retrovirus[J]. Biochem Biophys Res Commun，1992，183：879-885. [29] GAGNE J F，DESORMEAUX A. Targeted Delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes[J]. Biochem Biophys Acta，2002，1558(2)：198-210. [30] KONOPKA K，DUZGUNES N，ROSSI J，et al. Receptor ligand-facilitated cationic liposome delivery of anti-HIV-1 Rev binding aptamer and ribozyme DNAs[J]. J Drug Target，1998，5：247-259. [31] SLEPUSHKIN V A，SINOES S，DAZIN P，et al. Targeting of liposomes to HIV-infected cells by peptides derived from the CD4 receptor[J]. Biochem Biophs Res Commun，1996，227：827-833. [32] WANG X，ZHENG Y T，RONG L F，et al. Effects of galactosylceramide liposomes on HIV-1 infectivity[J]. Immunol J(免疫学杂志)，2002，18(2)：128-131. [33] AHMAD N，KHAN M A，OWAIS M. Liposome mediated antigen dilivery leads to induction of CD8+ T lymphocyte and antibody responses against the V3 loop region of HIVgp120[J]. Immunology，2001，210(1)：49-55. [34] DEVALINA L，ERIC A S，KENNAN C M，et al. Ritonavir-PEG 8000 amorphous solid dispersions： in vitro and in vivo evaluations[J]. J Pharm Sci，2004，93(3)：563-569. [35] PARK J，LEE S，KIM A . Microparticle and liquid formulation of a novel HIV protease inhibitor[J]. Pharm Dev Technol，2002，7(3)：297-303. [36] BOUDAD H，LEGRAND P，LEBAS G，et al. Combined hydroxypropyl-β-cyclodextrin and poly (alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir[J]. Int J Pharm，2001，218：113-124. [37] WEARLEY L，CHIEN Y W. Aids and chemotherapy[J]. Drugs Today，1989，25：19-25. [38] DAE-DUK K，YIE W C. Transdermal delivery of dideoxynucleoside-type anti-HIV drugs. 2. The effect of vehicle and enhancer on shin permeation[J]. J Pharm Sci，1996，85(2)：214-219. [39] SUNIL T K N，RAMESH P. Transdermal delivery of zidovudine： effect of terpenes and their mechanism of action[J]. J Controlled Release，2004，95：367-379. [40] TEN R M，ANDERSON P M，ZEIN N N，et al. Interleukin-2 liposomes for primary immune deficiency usine the aerosol route[J].Int Immunopharmacol ，2002，2(2-3)：333-344. [41] WINTERQERST U，ROLINSKI B，BOGNER J R，et al. Pharmacokinetics of Zidovudine after rectal administration in human immunodeficiency virus-infected patients[J]. Antimicrob Agents Chemothe，1997，41(5)：1143-1145.